Pathway analysis by Li et al. revealed an activation of the RAS/MEK/ERK pathway and inhibition of TP53 by HERV-K (HML-2) in pancreatic cancer cells [322], which was confirmed in breast cancer cells by Lemaître et al. (2017) (see Results HERVs in Breast Cancer—The Rise of New Biomarkers) [77]. Here, TP53 is linked to breast carcinoma.